John T Hays, MD

Office Locations:

Medical Park Tower (Central Austin), Austin Heart - Taylor

Personal Interests:

Boating, water skiing, salt water fishing, hunting and hiking

Professional Associations:

• American College of Cardiology
• American College of Physicians
• American Medical Association
• Society of Nuclear Medicine
• Texas Medical Association
• Travis County Medical Society

Professional Affiliations:

• Cardiology Section Chief, Seton Hospital System
• Medical Executive Committee, Seton Hospital System
• Chair, Education Committee, Austin Heart

Publications

• Grinstead WC, Noon GP, Sekela ME, Samo T, Verani MS, Hays JT, Young JB. Pseudomonas pulmonary artery graft endocarditis in heterotopic heart transplant: Case presentation and literature review. Clin Transplantation 1992;6: 301-305
• Hays JT, Mahmarian JJ, Cochran AJ, Verani MS. Dobutamine Thallium-201 Single-photon emission tomography in the evaluation of patients with suspected coronary artery disease unable to undergo exercise or pharmacologic vasodilation. J Am Coll Cardiol 1993;21: 1583-1590
• Hays JT, Hamill RD, DeFelice CA, Raizner AE: Coronary artery spasm culminating in thrombosis following ergonovine stimulation. Cathet Cardiovas Diag 1993;13: 181-193.
• Verani MS, Nishimura S, Mahmarian JJ, Hays JT, Young JB. Cardiac function after orthotopic heart transplant: Response to postural changes, exercise and Beta-adrenergic blockade. J Card Transplantation 1994;13: 181-193
• Hays JT, Stein B, Raizner AE. The crumpled coronary artery: Its potential for Misinterpretation. Cathe and Cardiovas Diag 1994; 31: 181-193
• He ZX, Medrano R, Hays JT, Mahmarian JJ, Verani MS. Nitroglycerin-Augmented Thallium-201 reinjection enhances detection of reversible Myocardial Hypoperfusion Circulation 1997; Vol 95, No 7: 1799-1805

Abstracts:

• Hays JT, Mahmarian JJ, Verani MS. Dobutamine thallium-201 single-photon Emission tomography in the evaluation of patients with suspected Coronary artery disease unable to undergo exercise or pharmacologic vasodilation. J Nuclear Med 1991; 21: 979
• Hays JT, Nishimura S, Mahmarian JJ, Verani MS. Reinjection of thallium-201: Is it really superior to four hour redistribution images? J Nuclear Med 1991;21: 948-949
• Cochran AJ, Hays JT, Mahmarin JJ, Verani MS. Dobutamine thallium-201 Tomography: A new method for evaluation patients with suspected coronary artery disease. J Nuclear Med 1991; 32
• Baker WE, Hays JT, Mahmarian JJ, Verani MS, Zoghbi W. Comparison of dobutamine echocardiography with simultaneous thallium-201 SPECT in the diagnosis of CAD. Circulation 1991; 84: (II): 1898 (II)
• Mahmarian JJ, Hays JT, Ashmore RF, Cochran AJ, Verani MS. Dobutamine with Thallium-201 single photon tomography: an alternative stress method for detecting the presence and extent of CAD in patients unable to exercise. J AM Coll Cardiol 1991; 17 (suppl A): 55 (A)
• Grinstead WC, Raizner AE, Churchhill DA, Hays JT, Kleiman NS, Joseph J, Voorhess WD, Fearnot N, Roubin GS, George BS, Pinkerton C, King SB. Intracoronary thrombosis prior to stenting: Impacting on angiographic success and clinical outcome. J Am Coll Cardiol 1993; 29: 77
• Lowry RW, Tawa C, Hays JT, Churchill D, Grinstead WC, Kleiman NS. Which Factors predict successful reattachment of angioplasty-induced dissections using perfusions balloons? Cathet Cardiovasc Diag 1993; 29:87
• Churchhill DA, Raizner AE, Grinstead WC, Hays JT, Kleiman NS, Roubin GS, George BS, Pinkerton CA, Voorhees W. Intracoronary stenting in the elderly: Safety and Efficacy. Cathet Cardiovasc Diag 1993; 29:87
• Hays JT, Kleiman NS, Grinstead WC, Churchhill DA, Jospeh J, Voorhees W, Fearnot NE, Roubin GS, Raizner AE. Effect of gender difference on clinical outcome among patients undergoing stent placement. Cathet Cardiovasc Diag 1993; 29:87
• Hays JT, Churchill DA, Tawa C, Marks GF, Tracy RP, Raizner AE, Kleiman NS. Rest angina following restenosis is characterized by a variable freaquency of thrombosis. Submitted to American Heart Association 66Th Scientific Sessions, November 1993
• Churchill DA, Hays JT, Grinstead WC, Chesnick PA, Raizner AE. Evaluation of a new femoral vessel compression device in high patients following interventional cardiology procedures. Submitted to American Heart Association 66th Scientific Sessions. November 1993
• Afridi I, Hays JT, Churchill DA, Zoghbi WA. Time course of recovery of regional ventricular function in the hibernating myocardium following coronary angioplasty. Submitted to American Heart Association 66th Scientific Sessions. November 1993
• Afridi I, Churchill DA, Hays JT, Zoghbi WA, Dobutamine echocardiography in Myocardial hibernation: Accuracy for predicting recovery of ventricular function following coronary angioplasty. Submitted to the American Heart Association 66th Scientific Sessions. November 1993

Research:

• ALIVE-A Double-Blind, Placebo-Controlled, Parallel Design Study to Determine the Effect of 75 mg or 100 mg of Orally Administered Azimilide Dihydrochloride versus Placebo on Survival in Recent Post-Myocardial Infarction Patients at Risk of Sudden Death, Proctor an Gamble Pharmaceuticals, Inc. (10/1997-01/2001)
• OPUS-TIMI-16 Trial- Orbofiban in Patients with Acute Coronary Syndromes, G.D. Searle & Company (09/1998-12/1998)
• BRAVO-Blockade of the GP IIB/IIIA Receptor to Avoid Vascular Occlusion, SmithKline Beecham (6/1999-06/2001)
• PRESTO-Prevention of Restenosis with Tranolast and its Outcomes: A Placebo-Controlled Trial, SmithKline Beecham (6/1999-06/2001)
• SUPORT-Stent Scaffolding by IVUS: Comparison of NIR vs. ACS Multilink Duet or AVE GFX 2 Coronary Stents, Boston Scientific Scimed (04/2000-08/2001)
• FASTER-An Open-Labeled, Randomized, Parallel, Dose-Finding (Dose-Ranging) Study of TNK-TPA in Combination with Aggraset in the treatment of Acute Myocardial Infarction, Merck (05/2000- 12/2001)
• GUARDIAN- a Double-Blind, Placebo-Controlled, Multinational Trail to Investigate the Effect of the Na/H Exchange Inhibitor HOE 642 (Cariporide) on All cause Mortality and Myocardial Infarction in Patients at Risk of Myocardial Necrosis Due to Acute Coronary Syndrome Related to the Disease Process or to an Interventional Cardiac Procedure, Hoechst Marion Roussel (09/1997-09-1998)
• ULTRA- Utilizing the GFX 2.5 mm Stent in Small Diameter Arteries: Acute and Threatened Closure Registry, Arterial Vascular Engineering, Inc. (05/1998-10/1998)
• LIMIT AMI- A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Angiographic Trial of the Safety and Efficacy of rhuMAb CD18 in Acute Myocardial Infarction, Genentech, Inc. (09/1998-03/2000)
• An Open-Label, Community-Based Clinical Practice Study in Niaspan Patients with Hyperlipidemia, KOS Pharmaceuticals, Inc. (09/1998-12/2000)
• The Effect of Sustained-Release Moxonidine on Mortality and Morbidity in Patients with Congestive Heart Failure, Eli Lilly and Company (01/1999-10/1999)
• VALIANT-Multinational, Multi-Center, Double-Blind, Randomized, Active Controlled, Parallel Group Study Comparing the Efficacy and Safety of Long-Term Treatment with Valsartan, Captopril and their Combination in High Risk Patients after Myocardial Infarction, Novartis, (05/2000-12/2003)
• OCTIVE- Multicenter, Randomized, Placebo- Controlled, Elective Titration Design of Omapatrilat (Vanlev) in Subjects with Uncontrolled Hypertension, Bristrol-Myers Squibb (11/2000-07/2001)
• ENABLE-2- A Double-Blind, Randomized, placebo-controlled study to assess the effects for Ro 47-0203 (Bosentan) on the Morbidity and Mortality of patients with Chronic Heart Failure. Actelion Ltd. (06/2000-07/2002)
• VIAGRA ED/CAD Study-A double-blind, randomized, Placebo-controlled, parallel group, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra in males with erectile dysfunction and coronary artery disease. Pfizer (01/2001-01/2002)
• REVIVE Study- Randomized, multicenter evaluation of intravenous levosimendan efficacy vs placebo in the short term treatment of decompensated Chronic heart failure. Orion Pharma (04/2002-12/2003)
• SYNERGY Trial- A prospective, randomized, open-label, multicenter study in high-risk patients presenting with Acuter Coronary Syndrome (ASC) Aventis Pharmaceuticals (01/2002-present)
• CREST Trail- A double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy of Cilostazol (Pletal) on prevention of restenosis after coronary intervention with stent implantation into a native coronary artery. Otsuka Pharmaceuticals. (02/2002-01/2004)
• TAXUS IV-Multicenter, Randomized, double-blind, controlled trial evaluating the Paclitaxel Coated Express Stent in treatment of coronary artery de novo lesions, Boston Scientific (04/2002-01/2004)
• EVIVE Study- Randomized, multicenter evaluation of intravenous Levosimendan efficacy vs. placebo in the short term treatment of decompensated Chronic Heart Failure. Orion Pharma (04/2002-12/2003)
• VIBRANT-Value of Information Based from Pacemaker Recordings and New Technologies. Vitatron Company (01/2003-present)
• A Phase 3 Clinical Trail to Assess Perfusion and Obstruction Identified by Non-invasive Technology using PB127 Ultrasound Contrast Agent in Patients with Suspected Obstructive Coronary Artery Disease ?Cardiosphere? Point BioMedcial Co. (10/2002-01/2004)
• JUMBO-TIMI-26-A double-blind, randomized Multicenter, dose-ranging trial of CS-747 compared with Clopidogrel in subjects undergoing Percutaneous Coronary Intervention, Eli Lilly & Co. (03/2003-02/2004)
• BSC-ELECT- Elective stenting of coronary arteries on liberte? System. Boston Scientific Corp. (04/2003-present)
• CYPHER- Stent Post Marketing Surveillance Registry Plan ?eCYPHER? Stent registry, Cordis Corporation (09/2003-present)
• A phase I pharmacokinetics dose-ranging trial of CARDIOsphere, PB127 Ultrasound Contrast Agent administered with non-PVC Plastic bags compared to glass bottles ?CSP 127-011? Point Biomedical Corp. (01/2004- Present)
• EVEREST-Multicenter, randomized, double-blind, placebo-controlled study to evaluate the long term efficacy and safety of oral Tolvaptan tablets in subjects hospitalized with worsening congestive heart failure. Otsuka Maryland Research Institute. (08/2003-present)

Medical Education & Training

Medical School: University of Texas Medical School, Houston, TX
Residency: Baylor College of Medicine, Houston, TX
Fellowship: Baylor College of Medicine, Houston, TX
Specialty Board Certifications: Internal Medicine, Cardiovascular Disease

Gender

Male

Languages

English, Spanish

John T Hays, MD

Specialty

Cardiovascular Diseases

John T Hays, MD

Billing

(512) 206-4300

Office Locations